NCT00124397 Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study) Status COMPLETED Phase PHASE4
NCT00123058 Comparison of Two Programs to Improve Blood Pressure Treatment Adherence Status COMPLETED Phase NA
NCT00122083 An Evaluation of the Effectiveness of a Simple Marketing Intervention in Changing Student Attitudes to Depression Status COMPLETED Phase NA
NCT00119769 The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Status COMPLETED Phase PHASE4
NCT00118014 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Status COMPLETED Phase PHASE4
NCT00117598 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Status COMPLETED Phase PHASE3
NCT00113529 Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT00113516 A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer Status COMPLETED Phase PHASE2
NCT00112073 AAB-001 in Patients With Mild to Moderate Alzheimer's Disease Status COMPLETED Phase PHASE2
NCT00110396 Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis Status COMPLETED Phase PHASE3
NCT00108433 Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Status TERMINATED Phase PHASE3
NCT00106639 A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients Status COMPLETED Phase PHASE2
NCT00106353 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT00106054 Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases Status TERMINATED Phase PHASE2
NCT00102895 A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer Status TERMINATED Phase PHASE2
NCT00101686 Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine. Status COMPLETED Phase PHASE3
NCT00098748 Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced NonCCR5-Tropic HIV-1 Infected Subjects Status COMPLETED Phase PHASE2/PHASE3
NCT00098722 Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects Status COMPLETED Phase PHASE2/PHASE3